February 11, 2026
A year of progress by ECOG-ACRIN and PrECOG in breast cancer, leukemia, lung cancer, and melanoma
November 3, 2025
The latest discoveries from breast, leukemia, lung, nose/sinus, skin, and throat cancer clinical trials
May 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
September 26, 2024
Adding immunotherapy to standard chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival
July 2, 2024
This study compares a standard initial treatment with a new approach that has the potential to put more patients into remission
January 5, 2023
Adding immunotherapy to standard chemotherapy keeps most patients in remission and improves their survival
June 28, 2022
This trial is for patients who have leukemia cells still in the blood or bone marrow after initial treatment
March 24, 2022
Summaries of recently reported ECOG-ACRIN research results
December 15, 2021
Summaries of leukemia, lymphoma, and myeloma research results
October 14, 2019
The combination of ibrutinib plus rituximab was superior to standard treatment for CLL patients age 70 and younger.